Loss of heterozygosity on chromosome 19 in secondary glioblastomas

Journal of Neuropathology and Experimental Neurology

Volumn 59, Issue 6, 2000, Pages 539-543

  Nakamura, Mitsutoshi ^a   Yang, Fan ^a   Fujisawa, Hironori ^a   Yonekawa, Yasuhiro ^b   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

LOH on chromosome 19; Primary glioblastoma; Secondary glioblastoma

Indexed keywords

ARTICLE; CHROMOSOME 19; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0034084423     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/59.6.539     Document Type: Article

References (47)

1. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26
2. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-36
3. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-24
4. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997;94:303-9
5. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-89
6. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology 1999;1:44-51
7. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-30
8. Fujisawa H, Reis R, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72
9. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter. Am J Pathol 1999;155:387-94
10. von Deimling A, Nagel J, Bender B, et al. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994;57:676-80
11. 1. Cancer Res 1994;54:1397-1401
12. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53
13. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-21
14. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72
15. Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 1995;12:277-82
16. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95
17. Yong WH, Chou D, Ucki K, et al. Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 1995;54:622-26
18. Rosenberg JE, Lisle DK, Burwick JA, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996;13:2483-85
19. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52
20. Hulsebos TJ, Oskam NT, Troost D, Leenstra S, Bijleveld EH. Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Cancer 1998;23:153-58
21. Müller MB, Schmidt MC, Schmidt O, et al. Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. J Neuropathol Exp Neurol 1999;58:40-45
22. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104
23. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90: 1473-79
24. Brüstle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer 1992;69:2385-92
25. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19
26. Chou D, Miyashita T, Mohrenweiser HW, et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996;88:136-40
27. Yong WH, Ueki K, Chou D, et al. Cloning of a highly conserved human protein Serine-Threonine phosphatase gene from the Glioma candidate region on chromosome 19q13.3. Genomics 1995;29: 533-36
28. Bello MJ, Vaquero J, de Campos JM, et al. Molecular analysis of chromosome I abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994;57: 172-75
29. Bello MJ, Leone PE, Nebreda P, et al. Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995;83:160-64
30. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19
31. Lees JA, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13: 7813-25
32. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997;272:14272-76
33. Kemper O, Derre J, Cherif D, Engelmann H, Wallach D, Berger R. The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Hum Genet 1991;87: 623-24
34. Bodmer JL, Burns K, Schneider P, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 1997;6:79-88
35. Wu GS, Burns TF, McDonald ER, et al. KILLER/DR5 is a DNA damage-inducible p53-reguluted death receptor gene. Nat Genet 1997;17:141-43
36. Rasio D, Murakumo Y, Robbins D, et al. Characterization of the human homologue of RAD54: A gene located on chromosome 1p32 at a region of high loss of heterozygosity in breast tumors. Cancer Res 1997;57:2378-83
37. Lapointe J, Lachance Y, Labrie Y, Labrie C. A p18 mutant defective in CDK6 binding in human breast cancer cells. Cancer Res 1996;56:4586-89
38. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ 1998;9:897-903
39. Mai M, Huang H, Reed C, et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-63
40. Sunahara M, Ichimiya S, Nimura Y, et al. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 1998;13:319-23
41. Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-83
42. Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 1998;58:2076-77
43. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998;57:122-30
44. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-46
45. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10: 1673-75
46. Gudmundsson J, Johannesdottir G, Bergthorsson JT, et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-32
47. Tsuzuki T, Tsunoda S, Sukaki T, Konishi N, Hiasa Y, Nakamura M. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 1996;78:287-93